Sumitomo Dainippon Pharma

News Releases

Jan. 10, 2019 (PDF/86KB)R&D

Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase III Clinical Study (JEWEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
Dec. 28, 2018 (PDF/72KB)Corporate

Correction to "Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S."
Dec. 25, 2018 (PDF/103KB)Corporate

Merger of DS Pharma Biomedical and DS Pharma Promo
Dec. 21, 2018 (PDF/127KB)R&D

Kyoto University's Center for iPS Cell Research and Application, Sumitomo Chemical, and Sumitomo Dainippon Pharma Commence Joint Research on Producing Higher-Quality iPS Cells for Clinical Use
Dec. 05, 2018 (PDF/39KB)Corporate

Sumitomo Dainippon Pharma Announces Resolution of Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S.

more
RSS

Other Notices

Dec. 03, 2018Others

Posted Factbook 2018 ver.2
Sep. 27, 2018CSR (PDF/179KB)

Sumitomo Dainippon Pharma Selected as a Component of Dow Jones Sustainability Indices (DJSI) for the second Consecutive Year
Sep. 27, 2018CSR (PDF/186KB)

Sumitomo Dainippon Pharma Receives the Award of Gold Class in Overall Category of SUSTAINA ESG AWARD 2018

more
RSS

IR Library

Research and Development

Aiming to create innovative pharmaceutical products
CSR

Targeting sustainable growth
Overseas Local Subsidiaries

Leading our global expansion